Stephan Ludwig

Has grant

Full Professor and Director

Westfälische Wilhelms Universität Münster Medizinische Fakultät

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Stephan Ludwig is a Full Professor and Director at Westfälische Wilhelms Universität Münster Medizinische Fakultät, Germany. His research areas include host-targeted antiviral therapies for SARS-CoV-2, the susceptibility of influenza viruses to antiviral agents, and the pathophysiological mechanisms of viral infections. Recent publications reflect his focus on viral resistance, immune responses in vaccinated populations, and innovative testing methods for quantifying antibody responses against SARS-CoV-2.

Recent Grants

Grant: Close

CoIMMUNE - Verwendung von humanen Lungenexplantaten zur prä-klinischen Evaluation von immunmodulatorischen Ansätzen zur Behandlung von COVID-19 ausgelöst durch SARS-CoV-2

Open Date: 2020-07-01

Close Date: 2021-12-31

Grant: Close

CoPREDICT - Covid-19 - Evaluation von Präventionstrategien durch agentenbasierte Simulationen

Open Date: 2020-06-01

Close Date: 2021-11-30

Grant: Close

EPIPREDICT - Benutzerorientierte Erweiterung und Automatisierung der agentenbasierten Software zur erregerspezifischen Modellierung vom Epidemien

Open Date: 2020-03-01

Close Date: 2022-02-28

Grant: Close

The role of MAPK pathways in SARS CoV-2 infection and COVID-19 disease (B13#)

Open Date: 2020-01-01

Close Date:

Grant: Close

KFO 342: Organ Dysfuncion During Systemic Inflammation

Open Date: 2019-01-01

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (22)

Anja E. Hauser

GERMANY

Stephan Ludwig

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib

SARS-CoV-2 Variant-Specific Antibodies in Vaccinated Inflammatory Bowel Disease Patients

Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment?

The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance

Small Spleen Peptides (SSPs) Shape Dendritic Cell Differentiation through Modulation of Extracellular ATP Synthesis Profile

MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases

Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells

Pathophysiological Mechanisms of Cardiac Dysfunction in Transgenic Mice with Viral Myocarditis

Cell-intrinsic genomic reassortment of pandemic H1N1 2009 and Eurasian avian-like swine influenza viruses results in potentially zoonotic variants

Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort

Glycolytic interference blocks influenza A virus propagation by impairing viral polymerase-driven synthesis of genomic vRNA

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients

Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2

Human lungs show limited permissiveness for SARS-CoV-2 due to scarce ACE2 levels but virus-induced expansion of inflammatory macrophages.

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs

3D <i>ex vivo</i> tissue platforms to investigate the early phases of influenza A virus- and SARS-CoV-2-induced respiratory diseases.

Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond

<i>Hypericum perforatum</i> and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2

Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases

SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids.

Collaborators (22)

Anja E. Hauser

M. Zeeshan Chaudhry

Carsten Theiss

Yvonne Börgeling

Giuliano Ciarimboli

Morris Baumgardt

Ursula Rescher

Anne Balkema-Buschmann

Matthias Behrens

Alexander Mellmann

Susann Kummer

Sefer Elezkurtaj

Cornelius Faber

Christine Goffinet

Yotam Menuchin-Lasowski

Jens C. Rueckert

Karin Klingel

Wolfgang A. Linke

Benedikt Obermayer

Georg Hempel

Anna Pascual Reguant

Markus Landthaler

Make your next move.